keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab AND radiotherapy

keyword
https://www.readbyqxmd.com/read/29050332/survival-outcomes-based-on-systemic-agent-used-concurrently-with-radiation-in-human-papillomavirus-associated-oropharyngeal-cancer
#1
Vikas Mehta, Tara Moore-Medlin, Jose M Flores, Xiaohui Ma, Oleksandr Ekshyyan, Cherie-Ann O Nathan
PURPOSE: To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences. STUDY DESIGN: A single institution retrospective analysis of 304 patients. The primary outcomes of interest were 1) overall survival and 2) relapse free survival...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28939061/chemoradiotherapy-for-locally-advanced-squamous-cell-carcinoma-of-the-oropharynx-does-completion-of-systemic-therapy-affect-outcomes
#2
Michael Baine, Tim Dorius, Nathan Bennion, Morshed Alam, Lynette Smith, Weining Zhen, Apar Ganti
INTRODUCTION: Current standard of care for locally advanced squamous cell carcinoma of the oropharynx (LA-OPC) consists of concurrent chemoradiotherapy. Due to toxicities associated with this treatment, a significant portion of patients are unable to complete the systemic therapy portion of their treatment course. The impact of incomplete systemic therapy on patient outcomes remains unclear. METHODS: Demographic, treatment, and outcome data were retrospectively collected for patients with LA-OPC treated definitively with concurrent chemoradiotherapy between 2007 and 2014...
October 2017: Oral Oncology
https://www.readbyqxmd.com/read/28932643/clinical-relevance-of-tumor-infiltrating-lymphocytes-pd-l1-expression-and-correlation-with-hpv-p16-in-head-and-neck-cancer-treated-with-bio-or-chemo-radiotherapy
#3
Dan Ou, Julien Adam, Ingrid Garberis, Pierre Blanchard, France Nguyen, Antonin Levy, Odile Casiraghi, Philippe Gorphe, Ingrid Breuskin, François Janot, Stephane Temam, Jean-Yves Scoazec, Eric Deutsch, Yungan Tao
To investigate the prognostic value of tumor infiltrating lymphocytes (TILs: CD8+ and FoxP3+), and PD-L1 expression in patients with head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy combined with cisplatin (CRT) or cetuximab (BRT). Immunohistochemistry for CD8, FoxP3 was performed on pretreatment tissue samples of 77 HNSCC patients. PD-L1 results were evaluable in 38 patients. Cox regression analysis was used to analyze the correlations of these biomarkers expression with clinicopathological characteristics and treatment outcomes...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28911062/tpf-plus-cetuximab-induction-chemotherapy-followed-by-biochemoradiation-with-weekly-cetuximab-plus-weekly-cisplatin-or-carboplatin-a-randomized-phase-ii-eortc-trial
#4
P M Specenier, E Remenar, J Buter, D L Schrijvers, C Bergamini, L F Licitra, A Awada, P M Clement, C Fortpied, J Menis, J B Vermorken
Background: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy. Methods: Patients with stage III/IV unresectable, squamous cell carcinoma of the head and neck received up to four cycles of TPF-E (cisplatin and docetaxel 75 mg/m2 on day 1 followed by 5-FU 750 mg/m2/day as a continuous infusion on days 1-5 plus cetuximab at a loading dose of 400 mg/m2 followed by a weekly dose of 250 mg/m2), with prophylactic antibiotics but no growth factors...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28867454/cetuximab-with-radiotherapy-as-an-alternative-treatment-for-advanced-squamous-cell-carcinoma-of-the-temporal-bone
#5
Koji Ebisumoto, Kenji Okami, Masashi Hamada, Daisuke Maki, Akihiro Sakai, Kosuke Saito, Fukuko Shimizu, Shoji Kaneda, Masahiro Iida
The prognosis of advanced temporal bone cancer is poor, because complete surgical resection is difficult to achieve. Chemoradiotherapy is one of the available curative treatment options; however, its systemic effects on the patient restrict the use of this treatment. A 69-year-old female (who needed peritoneal dialysis) presented at our clinic with T4 left external auditory canal cancer and was treated with cetuximab plus radiotherapy (RT). The primary lesion showed complete response. The patient is currently alive with no evidence of disease two years after completion of the treatment and does not show any late toxicity...
August 31, 2017: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/28864046/-radiotherapy-for-head-and-neck-squamous-cell-carcinoma-state-of-the-art-and-future-directions
#6
REVIEW
U Schick, F Huguet, Y Pointreau, O Pradier
Therapeutic principles of radiation therapy in head and neck carcinomas will be discussed in this review. Intensity-modulated radiotherapy with concomitant cisplatin should be standard. In case of contraindication to chemotherapy, cetuximab is an option, while hyperfractionation should be considered in patients unfit for concomitant treatment. Concomitant chemotherapy should be administered in the presence of extracapsular extensions and positive margins in the postoperative setting. Current research areas such as desescalation in human papillomavirus-positive tumours, adaptive radiotherapy, radiomics and immunotherapy will also be addressed...
October 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28860859/head-and-neck-cancer-improving-outcomes-with-a-multidisciplinary-approach
#7
REVIEW
Cristiana Lo Nigro, Nerina Denaro, Anna Merlotti, Marco Merlano
For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard treatment. The multidisciplinary approach, which includes multimodality treatment with S followed by RT, with or without chemotherapy (CT) or concurrent chemoradiotherapy (CRT), is required for locally advanced head and neck cancer (LAHNC). CRT improves prognosis, locoregional control (LRC), and organ function in LAHNC, compared to RT alone. Prognosis in recurrent/metastatic HNC (R/M HNC) is dismal. Platinum-based CT, combined with the anti-Epidermal Growth Factor Receptor (EGFR) antibody (Ab) cetuximab, is used in first-line setting, while no further validated options are available at progression...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28859058/preoperative-chemoradiation-with-capecitabine-irinotecan-and-cetuximab-in-rectal-cancer-significance-of-pre-treatment-and-post-resection-ras-mutations
#8
Simon Gollins, Nick West, David Sebag-Montefiore, Arthur Sun Myint, Mark Saunders, Shabbir Susnerwala, Phil Quirke, Sharadah Essapen, Leslie Samuel, Bruce Sizer, Jane Worlding, Katie Southward, Gemma Hemmings, Emma Tinkler-Hundal, Morag Taylor, Daniel Bottomley, Philip Chambers, Emma Lawrie, Andre Lopes, Sandy Beare
BACKGROUND: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. METHODS: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy with concurrent capecitabine, irinotecan and cetuximab. Resection was recommended 8 weeks later. The primary endpoint was histopathologically clear (R0) resection margin...
August 31, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28836950/concurrent-chemoradiotherapy-with-or-without-cetuximab-for-stage-ii-to-ivb-nasopharyngeal-carcinoma-a-case-control-study
#9
Yang Li, Qiu-Yan Chen, Lin-Quan Tang, Li-Ting Liu, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Ming-Yuan Chen, Xiang Guo, Ka-Jia Cao, Chao-Nan Qian, Mu-Shen Zeng, Jin-Xin Bei, Jian-Yong Shao, Ying Sun, Jing Tan, Shuai Chen, Jun Ma, Chong Zhao, Hai-Qiang Mai
BACKGROUND: This study aimed to evaluate the long-term outcome and toxicities in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated by concurrent chemoradiotherapy (CCRT) with/without adding cetuximab. METHODS: A total of 62 patients treated with CCRT plus cetuximab were matched with 124 patients treated with CCRT alone by age, sex, pathological type, T category, N category, disease stage, radiotherapy (RT) technique, Epstein-Barr virus (EBV) DNA levels, and Eastern Cooperative Oncology Group (ECOG)...
August 24, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28808428/a-comparison-of-concurrent-cisplatin-versus-cetuximab-with-radiotherapy-in-locally-advanced-head-and-neck-cancer-a-bi-institutional-analysis
#10
William A Stokes, Whitney A Sumner, Kiersten L Breggren, John T Rathbun, David Raben, Jessica D McDermott, Gregory Gan, Sana D Karam
AIM: To present our experience comparing cisplatin- and cetuximab-based radiotherapy for locally-advanced head and neck squamous cell carcinoma. BACKGROUND: The comparative effectiveness of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradiotherapy (BRT) for locally-advanced head and neck squamous cell carcinoma (LAHNSCC) continues to be explored. MATERIALS AND METHODS: Outcomes of LAHNSCC patients treated with CRT (125) or BRT (34) at two institutions were compared retrospectively, with attention to overall survival (OS), cancer-specific survival (CSS), locoregional control (LRC), and distant control (DC)...
September 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28807520/egfr-amplification-plus-gene-expression-profiling-predicts-response-to-combined-radiotherapy-with-egfr-inhibition-a-preclinical-trial-in-10-hnscc-tumour-xenograft-models
#11
Lydia Koi, Steffen Löck, Annett Linge, Cedric Thurow, Sandra Hering, Michael Baumann, Mechthild Krause, Kristin Gurtner
BACKGROUND AND PURPOSE: Improvement of the results of radiotherapy by EGFR inhibitors is modest, suggesting significant intertumoural heterogeneity of response. To identify potential biomarkers, a preclinical trial was performed on ten different human squamous cell carcinoma xenografts of the head and neck (HNSCC) studying in vivo and ex vivo the effect of fractionated irradiation and EGFR inhibition. Local tumour control and tumour growth delay were correlated with potential biomarkers, e...
September 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28753113/a-potential-therapy-for-chordoma-via-antibody-dependent-cell-mediated-cytotoxicity-employing-nk-or-high-affinity-nk-cells-in-combination-with-cetuximab
#12
Rika Fujii, Jeffrey Schlom, James W Hodge
OBJECTIVE Chordoma is a rare bone tumor derived from the notochord and is resistant to conventional therapies such as chemotherapy, radiotherapy, and targeting therapeutics. Expression of epidermal growth factor receptor (EGFR) in a large proportion of chordoma specimens indicates a potential target for therapeutic intervention. In this study the authors investigated the potential role of the anti-EGFR antibody cetuximab in immunotherapy for chordoma. METHODS Since cetuximab is a monoclonal antibody of the IgG1 isotype, it has the potential to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) employing natural killer (NK) cells as effectors...
July 28, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28740554/concurrent-chemoradiotherapy-with-or-without-anti-egfr-targeted-treatment-for-stage-ii-ivb-nasopharyngeal-carcinoma-retrospective-analysis-with-a-large-cohort-and-long-follow-up
#13
Rui You, Yi-Jun Hua, You-Ping Liu, Qi Yang, Yi-Nuan Zhang, Ji-Bin Li, Chao-Feng Li, Xiong Zou, Tao Yu, Jing-Yu Cao, Meng-Xia Zhang, Rou Jiang, Rui Sun, Hao-Yuan Mo, Ling Guo, Ka-Jia Cao, Ai-Hua Lin, Ying Sun, Chao-Nan Qian, Jun Ma, Ming-Yuan Chen
We examined the benefits of the combination of anti-EGFR targeted treatment, cetuximab (CTX) or nimotuzumab (NTZ) and concurrent platinum-based chemoradiotherapy (CCRT) compared with CCRT alone in patients with stage II - IVb nasopharyngeal carcinoma (NPC). A total of 1,628 eligible patients with stage II - IVb NPC, who received CCRT (three cycles of 100 mg/m(2) cisplatin every 3 weeks with intensity-modulated radiotherapy) with or without CTX or NTZ between June 2009 and December 2013 were included in the analysis...
2017: Theranostics
https://www.readbyqxmd.com/read/28685354/a-multicenter-phase-2-study-on-the-feasibility-and-efficacy-of-neoadjuvant-chemotherapy-without-radiotherapy-for-locally-advanced-rectal-cancer
#14
Suguru Hasegawa, Saori Goto, Takuya Matsumoto, Koya Hida, Kenji Kawada, Ryo Matsusue, Takashi Yamaguchi, Ryuta Nishitai, Dai Manaka, Shigeru Kato, Yoshio Kadokawa, Satoshi Yamanokuchi, Junichiro Kawamura, Masazumi Zaima, Takahisa Kyogoku, Akiyoshi Kanazawa, Yukiko Mori, Masashi Kanai, Shigemi Matsumoto, Yoshiharu Sakai
BACKGROUND: This prospective multicenter phase 2 study aimed to evaluate the feasibility and efficacy of neoadjuvant chemotherapy (NAC) without radiotherapy for locally advanced rectal cancer (LARC). METHODS: Patients with LARC (cStage II and III) were included in the study. Those with cT4b tumor were excluded. Six cycles of modified FOLFOX6 (mFOLFOX6) plus either bevacizumab or cetuximab, depending on KRAS status, were administered before surgery. The primary end point of the study was the R0 resection rate...
July 6, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28598813/identification-of-a-novel-atm-inhibitor-with-cancer-cell-specific-radiosensitization-activity
#15
Amy J C Dohmen, Xiaohang Qiao, Anja Duursma, Ruud H Wijdeven, Cor Lieftink, Floor Hageman, Ben Morris, Pasi Halonen, Conchita Vens, Michiel W M van den Brekel, Huib Ovaa, Jacques Neefjes, Charlotte L Zuur
Treatment of advanced head and neck squamous cell carcinoma (HNSCC) is plagued by low survival and high recurrence rates, despite multimodal therapies. Presently, cisplatin or cetuximab is used in combination with radiotherapy which has resulted in minor survival benefits but increased severe toxicities relative to RT alone. This underscores the urgent need for improved tumor-specific radiosensitizers for better control with lower toxicities. In a small molecule screen targeting kinases, performed on three HNSCC cell lines, we identified GSK635416A as a novel radiosensitizer...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28597041/efficacy-and-safety-of-postoperative-bio-chemoradiotherapy-using-cetuximab-and-docetaxel-for-high-risk-head-and-neck-cancer-patients-in-japan
#16
Goshi Nishimura, Osamu Shiono, Daisuke Sano, Kenichiro Yabuki, Yasuhiro Arai, Yoshihiro Chiba, Teruhiko Tanabe, Nobuhiko Oridate
PURPOSE: To confirm the efficacy and safety of cetuximab and docetaxel in postoperative radiotherapy for high-risk head and neck cancer patients who cannot to be administered high-dose cisplatin. PATIENTS AND METHODS: The eligibility criteria required stage III-IVB head and neck cancer patients who had undergone total resection, and for whom pathological evaluation revealed positive or close margins in the primary site and/or extracapsular nodal extension and/or two or more nodal metastases...
July 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28580506/prolonged-overall-treatment-time-and-lack-of-skin-rash-negatively-impact-overall-survival-in-locally-advanced-head-and-neck-cancer-patients-treated-with-radiotherapy-and-concomitant-cetuximab
#17
Julien Roman, Gurvan Dissaux, Maelenn Gouillou, Yves Gobel, Gael Potard, Jean-Christophe Leclere, Virginie Conan-Charlet, Dorothy Gujral, Ronan Abgral, Briac Guibourg, Olivier Pradier, Ulrike Schick
BACKGROUND: Cetuximab, a chimeric monoclonal antibody against EGFR sensitizes tumors to radiotherapy (RT), but is associated with skin and mucosal toxicity. OBJECTIVE: We report outcomes and tolerance of definitive RT in association with cetuximab in patients with locally advanced squamous cell carcinoma (LASCC) of the head and neck. PATIENTS AND METHODS: Between 2006 and 2011, 92 consecutive patients with LASCC of the head and neck were treated with RT and concomitant weekly cetuximab...
August 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28577306/cetuximab-or-nimotuzumab-plus-intensity-modulated-radiotherapy-versus-cisplatin-plus-intensity-modulated-radiotherapy-for-stage-ii-ivb-nasopharyngeal-carcinoma
#18
Rui You, Rui Sun, Yi-Jun Hua, Chao-Feng Li, Ji-Bin Li, Xiong Zou, Qi Yang, You-Ping Liu, Yi-Nuan Zhang, Tao Yu, Jing-Yu Cao, Meng-Xia Zhang, Rou Jiang, Hao-Yuan Mo, Ling Guo, Ka-Jia Cao, Ai-Hua Lin, Chao-Nan Qian, Ying Sun, Jun Ma, Ming-Yuan Chen
To compare intensity-modulated radiotherapy (IMRT) with cisplatin (CDDP) versus cetuximab (CTX) and nimotuzumab (NTZ) for Stage II-IVb Nasopharyngeal Carcinoma (NPC). A total of 1,837 patients with stage II-IVb NPC who received IMRT plus CTX or NTZ, or CDDP between January 2009 and December 2013 were included in the current analysis. Using propensity scores to adjust for potential prognostic factors, a well-balanced cohort of 715 patients was created by matching each patient who underwent IMRT plus concomitant NTZ/CTX with four patients who underwent IMRT plus concomitant CDDP (1:4)...
September 15, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28557105/major-response-to-pembrolizumab-in-two-patients-with-locally-advanced-cutaneous-squamous-cell-carcinoma
#19
LETTER
E Degache, J Crochet, N Simon, M Tardieu, S Trabelsi, M Moncourier, I Templier, L Foroni, A Lemoigne, N Pinel, H Gil, L Bouillet, M T Leccia, J Charles
No abstract text is available yet for this article.
May 30, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28535302/inhibition-of-n-acetylglucosaminyltransferase-v-enhances-the-cetuximab-induced-radiosensitivity-of-nasopharyngeal-carcinoma-cells-likely-through-egfr-n-glycan-alterations
#20
Xiaomin Huang, Ting Liu, Qiongyao Wang, Weiliang Zhu, Hui Meng, Linlang Guo, Ting Wei, Jian Zhang
N-acetylglucosaminyltransferase V (GnT-V), an enzyme that catalyses the formation of the N-linked β-1-6 branching of oligosaccharides, is related to the radiosensitivity of nasopharyngeal carcinoma (NPC). Cetuximab (C225) is an epidermal growth factor receptor (EGFR) inhibitor used as a radiosensitizer in the treatment of NPC. In this study, we used GnT-V as a molecular target to further sensitize cetuximab-treated NPC cells to radiation. The results from two NPC cell lines (CNE1 and CNE2) revealed that the silencing of GnT-V enhanced cetuximab-induced radiosensitivity by decreasing the β-1-6 branching of oligosaccharides on the EGFR...
May 23, 2017: Glycobiology
keyword
keyword
104263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"